March Trial Set For Patent Battle Over Glaucoma Treatment
A Novartis AG eye-care spinoff is set to battle two generic-drug makers in long-running litigation over the validity of its glaucoma treatment patent at a trial starting in mid-March....To view the full article, register now.
Already a subscriber? Click here to view full article